Document |
Document Title |
WO/2009/018389A1 |
Described herein are cannabidiol prodrugs, methods of making cannabidiol prodrugs, formulations comprising cannabidiol prodrugs and methods of using cannabidiols. One embodiment described herein relates to the transdermal or topical admi...
|
WO/2009/016879A1 |
It is intended to provide a process for producing an optically active N-(halopropyl)amino acid derivative. This method comprises: the step wherein an optically active alanine ester represented by the formula (I) or its salt (hereinafter ...
|
WO/2009/013915A1 |
An inhibitor of plasminogen activator inhibitor-1 (PAI-1). A medicinal composition having an effect of inhibiting the PAI-1 activity and being efficacious in preventing or treating various diseases for the onset of which the PAI-1 activi...
|
WO/2009/007415A2 |
The invention provides compounds of general formula (I) or a pharmaceutically acceptable salt, polymorph or solvate thereof, including all tautomers and stereoisomers thereof, wherein K, W, X; Y and Z are described throughout the descrip...
|
WO/2009/007696A1 |
Compounds of formula (I) or formula (II) have dopaminergic activity: wherein: R1 is a carboxyl, carboxyl ester, or carboxamide group; R2 is a group - C(=O)-NR3R4, or -S(=O)2-NR3R4; R3 and R4 are independently selected from hydrogen, opti...
|
WO/2009/007259A1 |
A process for the preparation of indole derivatives of formula (I) which are useful as intermediates in the preparation of i.a. pharmaceutically active compounds.
|
WO/2009/004643A2 |
The present invention relates to an improved process for the preparation of (S)- Pregabalin of formula (I) and its intermediates thereof. Particularly, the present invention relates to the process for the preparation (S)-Pregabalin havin...
|
WO/2009/000775A1 |
The present invention relates to new on bead chemistry to produce compound libraries used in improved screening methods, allowing the direct solution confirmation of on-bead screening hits without compound decoding and resynthesis. More ...
|
WO/2008/156817A2 |
Described are compounds that bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compound...
|
WO/2008/151992A2 |
The present invention provides a novel method for preparing a key intermediate, 3-amino-pentan-l,5-diol (2), which is useful for the preparation of 6-(2,4- difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)-propylamino
]-8-methyl-8H- pyrid...
|
WO/2008/151785A1 |
The invention relates to a method for producing a compound which has at least one ether group, at least one ester group, at least one amino group or at least one urethane group, preferably at least one ester group. The method according t...
|
WO/2008/151784A1 |
The invention relates to a method for producing 1,2 propandiol by hydrogenation of glycerol using hydrogen gas, wherein glycerol is reacted with hydrogen to give 1,2 propandiol. This reaction is carried out in at least i reactors R1 to R...
|
WO/2008/148747A2 |
This invention relates to compounds useful as PDZ domain modulators, in particular the PDZ domain of PICK1. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions.
|
WO/2008/144635A1 |
Embodiments of the present disclosure include soil repellent compositions, methods for imparting resistance to soiling on a fibrous substrate, fibrous substrates to which a soil repellent composition has been applied and dried, methods o...
|
WO/2008/142100A1 |
The invention relates to an improved method for producing carbonate-terminated urethanes using isocyanates. The method according to the invention is characterized by high yields with no phenol being produced as a secondary component.
|
WO/2008/139467A2 |
The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N'-disucci...
|
WO/2008/138639A1 |
This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper- proliferative and/or angiogenesis disorde...
|
WO/2008/141099A1 |
A (-)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic.
|
WO/2008/137165A1 |
This invention includes, in part, methods of preparing glycated polypeptide antigens and antibodies that specifically recognize glycated epitopes on polypeptides. The invention also relates, in part, to the preparation and use of antibod...
|
WO/2008/135273A1 |
Urethane and oligourethane derivatives and corresponding uses and methods of producing watermarks using the offset printing technique. The invention relates to compounds having general formula (R-O-CO-NH-X-NH-CO-O-(-A-O-CO-NH-X'-NH-CO-O-...
|
WO/2008/134326A1 |
This invention is a composition comprising a regioisomeric branched aldehyde (2) where Boc is -C(O)OC(CH3)3 and optionally an additional aldehyde of formula (1). The invention is also a method of making the compositions.
|
WO/2008/129129A1 |
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted hetero...
|
WO/2008/124969A1 |
The present invention provides a preparation method of rivastigmine and its intermediates. The present invention provides a preparation method of the formula (1) compound by reacting the formula (2) compound with CH3X or CH3CH2X in the p...
|
WO/2008/125486A1 |
The invention relates to a process for the preparation of N-protected α-aminoaldehydes by deacetalization of the acetal functional group of corresponding N-protected α-aminoacetals using formic acid.
|
WO/2008/123207A1 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...
|
WO/2008/119804A1 |
The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a pr...
|
WO/2008/120475A1 |
Disclosed is a method for producing an alcohol from a lactone or a carboxylic acid ester, which enables to produce an alcohol from a lactone or a carboxylic acid ester under relatively mild conditions with high yield and high catalytic e...
|
WO/2008/120573A1 |
[PROBLEMS] With the purpose of providing an actinic radiation-cured product having high heat resistance and a high refractive index, the invention provides compounds which have specific structures bearing unsaturated groups; resin compos...
|
WO/2008/120567A1 |
Disclosed is a method for collecting an L-biphenylalanine compound salt (2'), which comprises the steps of: hydrolyzing a biphenylalanine ester compound (1) with a protease derived from a microorganism belonging to the genus Bacillus in ...
|
WO/2008/111300A1 |
Disclosed is a novel compound which has a potent FXa inhibition activity and exhibits a sufficient and sustained antithrombotic effect rapidly when administered orally. Specifically disclosed is: a compound represented by the general for...
|
WO/2008/110339A2 |
The invention relates to a crystalline rivastigmine hydrogentartrate of Form II.
|
WO/2008/110308A2 |
Cyclohexanedione compounds, and derivatives thereof, which are substituted in 5-position, are suitable for use as herbicides.
|
WO/2008/108735A1 |
The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and d...
|
WO/2008/107879A1 |
Novel derivatives of cannabidiol, having one or two of the hydroxyl groups substituted, exhibiting improved production yield, solubility, stability and bioavailability, are provided. Also provided are pharmaceutical compositions comprisi...
|
WO/2008/102680A1 |
Disclosed is a hyperbranched polymer having a main chain of polyamide structure and a terminal amino group, which does not require a large amount of an organic solvent during production. This hyperbranched polymer has high transparency a...
|
WO/2008/100977A2 |
Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. Esters of alkylcarbamic acids are disclosed that are inhibitors of FAAH activity. Compounds disclosed herein inhibit...
|
WO/2008/097546A2 |
Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a...
|
WO/2008/095841A2 |
The invention relates to nitric oxide donor compounds and their use for treating cardiovascular diseases, inflammation, pain, fever, gastrointestinal disorders, ophthalmic diseases, hepatic disorders, renal diseases, respiratory disorder...
|
WO/2008/096094A1 |
Representatives of compounds of formula (I) having M3 receptor antagonist activity; a composition comprising such a compound; the use of such a compound in therapy (such as asthma or COPD); and a method of treating a patient with such a ...
|
WO/2008/083967A2 |
The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, p...
|
WO/2008/084086A1 |
The present invention relates to a method for the production of o-vinylcarbamates or vinylcarbonates, wherein a secondary amine or an alcohol is reacted with an alkyne compound in the presence of a catalyst selected from among carbonyl c...
|
WO/2008/082881A1 |
Di-, tri-, and/or tetra-(meth)acryloyl-containing materials and compositions are provided. Such materials and compositions can preferably be hardened, without undue shrinkage, to provide hardened materials and/or compositions with proper...
|
WO/2008/081041A2 |
Rivastigmine hydrogentartrate in amorphous form or in a crystalline form characterized by an X-ray powder diffraction pattern exhibiting peaks at 2Θ values of 5.1, 14.7, 16.5, 17.6, 18.6, 20.4, 21.1° ± 0.2° (Form I), or 2Θ values of...
|
WO/2008/066900A1 |
This invention is directed to compounds of formula (I), where G is -O-, -S-, -C(g1)(g2)-, or -NH-, and n = 1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and ...
|
WO/2008/062859A1 |
A process for the production of phenylalanine derivatives having quinazolinedione rings as represented by the general formula (1) or pharmaceutically acceptable salts thereof:(1) which comprises the following steps (a), (b) and (c): the ...
|
WO/2008/059051A1 |
The invention relates to a process for the production of an imide (1) (2) (3) via the enantioselective addition of an amine (2) to an alkene (3) wherein Y is OR, wherein R is alkyl or Bn, said process comprising: incubating Pd(OTf)2 with...
|
WO/2008/059299A1 |
The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands fo...
|
WO/2008/059953A1 |
Disclosed is a method for stably producing an isocyanate with high yield for a long time without using phosgene. This method for producing an isocyanate does not cause the problems involved in the prior art. Specifically disclosed is a m...
|
WO/2008/054233A2 |
The process for preparation of docetaxel consists in that the hydroxyl groups at C-7 and C-IO position of 10- deacetylbaccatin III and the amino group of (4S,5R)-2- methoxyphenyl-4-phenyl-l, 3-oxazolidine-5-carboxylic acid are protected ...
|
WO/2008/052788A1 |
The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, derivatives thereof of the formula (I) and uses thereof are described.
|